2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for MOUNJARO, a human drug product, in response to a patent extension application submitted to the US Patent and Trademark Office (USPTO).
2/29/2024
The FDA has published a notice determining the regulatory review period for VONJO, a human drug product, following a patent extension application submitted to the USPTO, as required by law.
2/29/2024
The Food and Drug Administration (FDA) is seeking public comment on a proposed collection of information related to medical device user fees, as required by the Paperwork Reduction Act of 1995.
2/29/2024
The Food and Drug Administration (FDA) has determined the regulatory review period for CAMZYOS, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to the submission of patent extension applications to the US Patent and Trademark Office (USPTO), Department of Commerce.
2/29/2024
The FDA is issuing an order under the FD&C Act, stating that Timothy Baxter's debarment will end on October 26, 2025.
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for SAPHNELO, a human biological product, in response to patent extension applications submitted to the US Patent and Trademark Office (USPTO).
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the EPI-SENSE GUIDED COAGULATION SYSTEM, a medical device, in response to patent extension applications submitted to the US Patent and Trademark Office (USPTO).
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of TEMBEXA, a human drug product, following a submission to the US Patent and Trademark Office (USPTO).
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of the AMPLATZER AMULET medical device, following submissions to the US Patent and Trademark Office (USPTO) for patent extension.
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for EVKEEZA, a human biological product, following a submission to the US Patent and Trademark Office (USPTO) for patent extension.
2/29/2024
The Food and Drug Administration (FDA) has determined the regulatory review period for SOGROYA, a human biological product, and is publishing this notice as required by law. The FDA made this determination due to a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO), Department of Commerce.
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of human biological product ADUHELM, following a submission to the US Patent and Trademark Office (USPTO).
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for EVRYSDI's patent extension application, submitted to the US Patent and Trademark Office (USPTO), in accordance with federal law.
2/29/2024
The FDA has published a notice determining the regulatory review period for CAMCEVI, a human drug product, following a patent extension application submitted to the USPTO, as required by law.
2/29/2024
The Food and Drug Administration (FDA) has published a notice determining the regulatory review period for OPDUALAG's patent extension application, submitted to the US Patent and Trademark Office (USPTO) for a human biological product patent.
2/29/2024
The FDA has published a notice determining the regulatory review period for GEMTESA, a human drug product, following submissions to the USPTO for patent extension.
2/29/2024
The Food and Drug Administration (FDA) has published a notice determining the regulatory review period for VEKLURY, a human drug product, following submissions to the U.S. Patent and Trademark Office (USPTO) for patent extension.
2/29/2024
The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for NULIBRY, a human drug product, in response to a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).
2/29/2024
The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for XERAVA, a human drug product, following a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of PREVNAR-20, a human biological product, following submissions to the US Patent and Trademark Office (USPTO).
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for the patent extension of LEQVIO, a human drug product, following a submission to the US Patent and Trademark Office (USPTO).
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for ISTURISA, a human drug product, following submissions to the US Patent and Trademark Office (USPTO) for patent extension.
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for KLISYRI, a human drug product, in response to patent extension applications submitted to the US Patent and Trademark Office (USPTO).
2/29/2024
The U.S. Food and Drug Administration (FDA) has determined the regulatory review period for ONGENTYS, a human drug product, following a submission to the U.S. Patent and Trademark Office (USPTO), Department of Commerce. The FDA is publishing this notice as required by law.
2/29/2024
The US Food and Drug Administration (FDA) has published a notice determining the regulatory review period for INQOVI, a human drug product, in response to patent extension applications submitted to the US Patent and Trademark Office (USPTO).
2/29/2024
The Department of Justice has published a document in the Federal Register, requesting public comments on the reinstatement of a previously approved collection, the Census of Jails 2024-26, following the publication of an incorrect document on February 26, 2024.
2/29/2024
The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF), part of the Department of Justice (DOJ), is seeking OMB approval for a revision to a previously approved information collection, as required by the Paperwork Reduction Act of 1995.
2/29/2024
The Advisory Committee on Historical Diplomatic Documentation will hold in-person meetings in both open and closed sessions to discuss declassification and record transfer to the National Archives and Records Administration, as well as the status of the Foreign Relations series.
2/29/2024
The Department of Labor is seeking public comment on an information collection request sponsored by the Office of the Assistant Secretary for Administration and Management, which is required by the Paperwork Reduction Act of 1995 and must be reviewed and approved by the Office of Management and Budget.
2/29/2024
The Commodity Futures Trading Commission is extending the comment period for its proposed rule on real-time public reporting requirements and swap data recordkeeping and reporting requirements by 45 days, following the initial closure on February 26, 2024
2/29/2024
A proposed consent order aims to settle allegations of violating federal law by prohibiting unfair or deceptive acts or practices, as outlined in the attached analysis.
2/28/2024
For the purposes of Article 5 (4) and Article 9 (5) of the Code of Practice, we publish the results of our business executive evaluation for 2022 as follows: 48 points, 52 points, 100 points, 36.10 points, 48.82 points, 84.92 points (A-level)
2/28/2024
For the purposes of Article 5 (4) and Article 9 (5) of the Code of Conduct, we publish the results of our business practice assessment for 2023 as follows: ex-partnership index (x) 48 points (x), non-ex-partisan index (X) 52 points (X)) 100 points (xx) evaluation report 47.38 points (45.86 points) 93.24 points (S class).
2/28/2024
The World Health Organization is hosting a stakeholder listening session to discuss public health emergencies preparedness and response negotiations.
2/28/2024
The Administration for Community Living has submitted the proposed collection of information to the Office of Management and Budget for review and clearance, seeking comments on the extension of Performance Data for State Grants for Assistive Technology Program Annual Progress Report.
2/28/2024
The National Marine Fisheries Service (NMFS) is announcing a 2024 annual catch limit of 720 metric tons for U.S. commercial Pacific bluefin tuna fishing vessels in the eastern Pacific Ocean.
2/28/2024
The U.S. Court of International Trade issued a final judgment on February 8, 2024, sustaining the U.S. Department of Commerce's remand results for the antidumping duty order on multilayered wood flooring from China, but the court's decision is not in harmony with Commerce's final results.
2/28/2024
The U.S. Department of Commerce found Shanghai Yueda Nails Co., Ltd. sold certain steel nails from China at below-normal prices in the US between August 1, 2021, and July 31, 2022, while other companies made no shipments during the same period.
2/28/2024
The National Marine Fisheries Service (NMFS) proposes 2024 specifications and projected 2025 specifications for the Atlantic mackerel fishery to prevent overfishing, consistent with the most recent scientific information.
2/28/2024
The National Marine Fisheries Service (NMFS) has issued a permit to the California Department of Fish and Wildlife (CDFW) for the Fall Creek Hatchery coho salmon program in the Klamath River watershed in California.
2/28/2024
The National Marine Fisheries Service (NMFS) proposes revisions to regulations that implement the Pacific Fishery Management Council's Pacific Coast Salmon Fishery Management Plan, removing a rebuilding plan for Snohomish River coho salmon as it has been rebuilt.
2/28/2024
Coller Secondaries Private Equity Opportunities Fund and Coller Private Market Secondaries Advisors, LLC have the same name.
2/28/2024
The Securities and Exchange Commission (SEC) is adopting jointly issued amendments to the Supplemental Standards of Ethical Conduct for Members and Employees of the Securities and Exchange Commission, addressing ethical issues unique to the SEC.
2/28/2024
The Financial Industry Regulatory Authority, Inc. has filed Amendment No. 1 to a proposed rule change to amend FINRA Rule 2210, which would permit projections of performance of investment strategies or single securities in institutional communications.
2/28/2024
The applicant seeks deregistration, having made a liquidating distribution to its shareholders on July 31, 2023, and filed the application on October 18, 2023, with an amendment on February 13, 2024.
2/28/2024
The Bureau of Land Management (BLM) Colorado is proposing a supplementary rule for public lands in the Tres Rios and Gunnison Field Offices, implementing decisions on vehicle use, camping, and wildlife habitat protection.
2/28/2024
The US Department of the Interior is publishing a notice to make the Choctaw Nation of Oklahoma and the Chickasaw Nation Water Rights Settlement enforceable and effective.
2/28/2024
Fort Lewis College has completed an inventory of human remains in accordance with the Native American Graves Protection and Repatriation Act, determining a cultural affiliation with Indian Tribes or Native Hawaiian organizations in La Plata and Montezuma counties, Colorado.
2/28/2024
California State University Chico has completed an inventory of human remains and associated funerary objects in accordance with the Native American Graves Protection and Repatriation Act, determining a cultural affiliation with Indian Tribes or Native Hawaiian organizations in Butte County, California.
2/28/2024
The University of California, Riverside has completed an inventory of human remains in accordance with the Native American Graves Protection and Repatriation Act, determining a cultural affiliation with Indian Tribes or Native Hawaiian organizations in Ventura, CA.